Mersana Therapeutics, Inc.
MRSN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $38,697 | $36,902 | $42,816 | $176,688 |
| - Cash | $56,391 | $76,972 | $102,287 | $107,750 |
| + Debt | $2,293 | $20,621 | $24,624 | $28,598 |
| Enterprise Value | -$15,401 | -$19,449 | -$34,847 | $97,536 |
| Revenue | $11,009 | $3,056 | $2,754 | $16,361 |
| % Growth | 260.2% | 11% | -83.2% | – |
| Gross Profit | $11,009 | $2,769 | $2,754 | $16,361 |
| % Margin | 100% | 90.6% | 100% | 100% |
| EBITDA | -$7,068 | -$23,335 | -$23,032 | -$12,814 |
| % Margin | -64.2% | -763.6% | -836.3% | -78.3% |
| Net Income | -$7,545 | -$24,296 | -$24,123 | -$14,117 |
| % Margin | -68.5% | -795% | -875.9% | -86.3% |
| EPS Diluted | -1.51 | -4.87 | -4.85 | -2.86 |
| % Growth | 69% | -0.4% | -69.6% | – |
| Operating Cash Flow | -$3,192 | -$22,602 | -$29,326 | -$19,251 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,192 | -$22,602 | -$29,326 | -$19,251 |